Opportunity
Simpler Grants.gov #RFA-CA-27-008
NIH NCI Community Oncology Research Program Academic Community Sites Funding Opportunity
Buyer
National Institutes of Health
Posted
May 21, 2026
Respond By
September 18, 2026
Identifier
RFA-CA-27-008
NAICS
541715
This opportunity from the National Institutes of Health (NIH), via the National Cancer Institute (NCI), invites academic medical centers to lead NCI Community Oncology Research Program (NCORP) Academic Community Sites. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Program Focus: - Conduct cancer-related clinical trials and human subject research in community settings - Enhance generalizability and dissemination of research results - Improve participant representativeness in cancer studies - Eligible Applicants: - Academic medical centers with strong infrastructure and networks of community hospitals, oncology practices, public hospitals, and other healthcare centers - Foreign organizations and collaborations are not eligible - Funding Details: - Cooperative agreement (research grant) - Estimated total funding: $73,000,000 - Approximately 50 awards anticipated - Products/Services Requested: - No specific products or OEMs; participation in cancer research and clinical trials - Unique Requirements: - Focus on cancer control, prevention, treatment, and care delivery - Emphasis on community-based research and improving diversity in clinical trial participants
Description
This Notice of Funding Opportunity (NOFO) is for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Academic Community Sites. NCORP aims to enhance the generalizability and dissemination of clinical trial and other human subject research results through accrual in various community settings. The program engages cancer patient populations and organizations in rigorous studies focused on cancer control, prevention, treatment, and care delivery. Academic Community Sites are led by academic centers with networks of community hospitals and healthcare centers to improve participant representativeness in cancer-related clinical trials and research.